Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
Although the collapse of Silicon Valley Bank (SVB) is raising concerns among biotech companies and venture capital firms, the United States government has taken […]
How does the SVB collapse affect biotech companies? Read More »
Experts told a House subcommittee Wednesday that China’s government coordinates a strategy to steal U.S. intellectual property – and the waiver of COVID IP would
Congress shines a light on China’s strategy to steal U.S. IP Read More »
“Strong patents, and an efficient, predictable, and objective patent system, are critical to the seeds industry, which depends on patent-driven activities to fuel the
Strong IP protection for seeds key to enabling biotech innovation Read More »
On March 2, 2023, the Biotechnology Innovation Organization (BIO) and 50 other national organizations announced the start of a coalition to advance trust in
BIO joins Coalition for Trust in Health & Science Read More »
Pain is the number one reason most Americans go to the doctor is pain, says Cindy Steinberg, Director of Policy and Advocacy for the
Can biotech crack the code on pain medications? Read More »
While research into long COVID-19 is offering clues to causes and potential targets for treatment, defeating this debilitating condition, which impacts millions, requires a
BIO’s online conference invites biotech to fight long COVID Read More »
Already, 2023 is looking like a dynamic year for biotech on the state level as state legislatures nationwide get ready to tackle a few
4 things for biotech to watch in the 2023 state legislatures Read More »
The Biotechnology Innovation Organization (BIO) recently told the U.S. Patent and Trademark Office (USPTO) that proposed changes to the pharmaceutical patent process are flawed—and
BIO says that proposed changes to pharma patents would harm innovation Read More »
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
On Friday, the Biotechnology Innovation Organization (BIO) submitted biotech regulation comments on the Administration’s Request for Information (RFI) “Identifying Ambiguities, Gaps, Inefficiencies, and Uncertainties in
BIO submits comments on framework for biotech regulation Read More »
